R848 mono-therapy also primed the generation of tumor-specific IFNγ-producing CD4+ T cells (P=0.001) but not CD8+ T cells and there was no significant difference between R848 mono-therapy and obinutuzumab plus R848 combination therapy (P=0.27). The gene discussed is IFNG; the disease is neoplasm.